Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With CVD (Lp(a)HORIZON)

Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With CVD (Lp(a)HORIZON)
Recruiting
18 years - 80 years
All
Phase 3
28 participants needed
1 Location

Brief description of study

This is a pivotal phase 3 study designed to support an indication for the reduction of cardiovascular risk in patients with established CVD and elevated Lp(a)

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: dyslipidemia,hyperlipidemia,myocardial infarction,stroke,peripheral artery disease,hypercholesterolemia,elevated Lp(a)
  • Age: 18 years - 80 years
  • Gender: All

Male and Female Age 18-80 Lp(a) ≥ 70 mg/dL Myocardial infarction: ≥ 3 months Ischemic stroke: ≥ 3 months significant symptomatic peripheral artery disease

Updated on 04 Aug 2024. Study ID: 843988

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center